Li De-Min, Qi Rui-Han, Zhang Hong-Chun, Liao Xing, Xie Yan-Ming, Zhang Jun-Hua, Zhang Bo-Li
National Clinical Research Center for Respiratory Diseases, Center for Respiratory Diseases, the Department of Traditional Chinese Medicine Pulmonary Diseases, China-Japan Friendship Hospital, Beijing 100029, China.
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Zhongguo Zhong Yao Za Zhi. 2018 Dec;43(24):4759-4764. doi: 10.19540/j.cnki.cjcmm.20181009.006.
To clarify the clinical application of the group standard (T/CACM 1035-2017) of the Chinese Society of Traditional Chinese Medicine (TCM), the clinical practice guideline on traditional chinese medicine therapy alone or combined with community acquired pneumonia, and to understand the clinical applicability of the Guideline. The clinical workers trained in terms of the Guideline in hospitals at all levels in China were selected as the research objects. A total of 494 questionnaires on application evaluation and 511 questionnaires on applicability evaluation were collected to construct the database of the post-effect evaluation of the Guideline. Excel software was used for statistical analysis. The overall evaluation of the Guideline was 92.31%, 91.06%, 87.45% respectively in efficacy, safety and economy. The Guideline was well used in clinical application, and 99.41% of the patients were willing to follow the recommended scheme. The agreed ratio in rationality evaluation was 97.98%, 92.37%, 94.53% and 92.71% in treatment rules, syndrome differentiation and classification, prevention of complications, and rehabilitation method. The effective rate of the prescriptions recommended in the Guideline was all above 65%. More than 80% of the prescriptions were Tanreqing Injection, Yinqiao Powder, Qingjin Huatan Decoction, Maxing Shigan Decoction, Shengmai San and Shashen Maidong Decoction. Adverse reactions, unknown active components and economy of Chinese patent medicines were the important factors affecting drug use and efficacy, providing a clinical basis for updating and revising the standard.
为阐明中国中医药学会团体标准（T/CACM 1035-2017）《中医治疗社区获得性肺炎临床实践指南》的临床应用情况，了解该指南的临床适用性。选取全国各级医院中接受过该指南培训的临床工作者作为研究对象。共收集494份应用评价问卷和511份适用性评价问卷，构建指南后效评价数据库。采用Excel软件进行统计分析。该指南在疗效、安全性和经济性方面的总体评价分别为92.31%、91.06%、87.45%。该指南在临床应用中使用良好，99.41%的患者愿意遵循推荐方案。在治疗原则、辨证分型、并发症防治及康复方法的合理性评价中，认同率分别为97.98%、92.37%、94.53%和92.71%。该指南推荐方剂的有效率均在65%以上。超过80%的方剂为痰热清注射液、银翘散、清肺化痰汤、麻杏石甘汤、生脉散和沙参麦冬汤。中成药的不良反应、活性成分不明及经济性是影响用药及疗效的重要因素，为标准的更新修订提供了临床依据。
